Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pharmacoeconomics
; 36(2): 131-144, 2018 02.
Article
in En
| MEDLINE
| ID: mdl-28933002
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Asthma
/
Anti-Asthmatic Agents
/
Antibodies, Monoclonal, Humanized
Type of study:
Clinical_trials
/
Health_technology_assessment
Aspects:
Patient_preference
Limits:
Adult
/
Humans
Language:
En
Journal:
Pharmacoeconomics
Journal subject:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Year:
2018
Document type:
Article
Affiliation country: